Peptilogics is a technology company.
Peptilogics has raised $119.0M across 3 funding rounds.
Peptilogics has raised $119.0M in total across 3 funding rounds.
Peptilogics is a biotechnology company developing novel peptide therapeutics for serious and life-threatening diseases, particularly focusing on antimicrobial peptides to combat antibiotic-resistant infections.[1][2][3] Its lead product, PLG0206, is an investigational synthetic peptide antibiotic targeting periprosthetic joint infections (PJI), with potent activity against bacterial biofilms and an acceptable safety profile from Phase 1 studies; it has FDA Orphan Drug and Qualified Infectious Disease Product designations.[2][3] The company serves patients with hard-to-treat infections, orthopedic complications, and other unmet needs in inflammation and oncology, solving drug discovery challenges by designing peptides that combine small-molecule drug-likeness with biologic specificity using AI-driven platforms.[1][7] Growth momentum includes multiple patents (e.g., US-12087404-B2 for anti-infective designs), advancement to Phase 2/3 for PLG0206, and preclinical programs like PLG0301 for inflammation.[2][3]
Peptilogics was founded in 2013 by Jonathan Steckbeck, PhD, MBA, who serves as President, CEO, and Founder, to advance peptide therapeutics through a design-based drug discovery approach, initially spurred by the promise of engineered cationic antimicrobial peptides (eCAPs).[1][2][4] The idea emerged from overcoming limitations of traditional antimicrobial peptides, with early eCAP technology demonstrating broad-spectrum activity against resistant bacteria, including Gram-negatives, via non-lytic membrane disruption that delays resistance development.[4] Pivotal early traction included $1.3M in seed funding and $5.5M Series A in 2018 to support PLG0206's IND submission and Phase 1 trials, alongside securing patents and partnerships in computational biology and drug development.[2][4] Key leaders like Chief Technology Officer Nicholas Nystrom, PhD, and Chief Strategy Officer Atul Deshpande, PhD, MBA, have driven evolution toward scalable AI-integrated platforms.[2]
Peptilogics rides the wave of peptide therapeutics innovation, leveraging advances in synthesis, AI, and computing to unlock "Nature’s intended blockbusters" for undruggable targets amid rising antibiotic resistance, where up to 50% mortality occurs in untreatable Gram-negative infections.[1][4] Timing is critical as antimicrobial resistance escalates globally, with market forces like FDA incentives (Orphan Drug status) and unmet needs in hospital-acquired infections favoring rapid developers; peptides bridge small molecules and biologics for better specificity and potency.[1][3] The company influences the ecosystem by pioneering generative AI for peptide design, enabling partners to translate science into medicines and potentially reshaping drug discovery for infections, inflammation, and beyond.[1][2]
Peptilogics is poised for Phase 2/3 readouts on PLG0206 in 2026+, with preclinical assets like PLG0301 advancing amid partnerships, potentially yielding first approvals in high-need areas like PJI.[3] Trends in AI-accelerated biotech and antimicrobial innovation will propel growth, as computational platforms scale peptide exploration against resistance crises. Its influence may expand through licensing eCAP tech or oncology/inflammation expansions, solidifying Peptilogics as a leader in precision peptide drugs—ushering the new era its founders envisioned.[1][7]
Peptilogics has raised $119.0M in total across 3 funding rounds.
Peptilogics's investors include AAF Management Ltd., Founders Fund, Presight Capital, Tachyon Ventures, Stefan Roever, Calm/Storm Ventures, Thiel Capital.
Peptilogics has raised $119.0M across 3 funding rounds. Most recently, it raised $78.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $78.0M Series B | AAF Management Ltd., Founders Fund, Presight Capital, Tachyon Ventures, Stefan Roever | |
| Dec 1, 2020 | $35.0M Series B | AAF Management Ltd., Calm/Storm Ventures, Founders Fund, Presight Capital, Tachyon Ventures, Thiel Capital, Stefan Roever | |
| Sep 1, 2017 | $6.0M Series A | AAF Management Ltd., Calm/Storm Ventures, Founders Fund, Presight Capital, Tachyon Ventures, Thiel Capital |